AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05232279
Drug: Testofen 300mg
RxNorm normalized name: Ketofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testofen in capsule form - To be taken as a 300mg dosage (2 capsules) once daily for 12 weeks.
Trial: NCT05232279
Drug: Testofen 600mg
RxNorm normalized name: Ketofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testofen in capsule form - To be taken as a 600mg dosage (2 capsules) once daily for 12 weeks.
Trial: NCT05232279
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will consist of maltodextrin and will appear identical to the Testofen capsules. The placebo will be administered as per the active treatment - 2 capsules once daily for 12 weeks.
Trial: NCT04770467
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given by intravenous administration
Trial: NCT05825066
Drug: mFOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician.
Trial: NCT04806061
Drug: standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard care
Trial: NCT05410925
Drug: Recombinant staphylokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
Trial: NCT05410925
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of placebo is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
Trial: NCT06284460
Drug: ASTX029
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT06284460
Drug: ASTX727
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT06096090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration
Trial: NCT05507567
Drug: Neumifil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid for intranasal spray administration
Trial: NCT05507567
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid for intranasal spray administration
Trial: NCT05349968
Drug: Lipovirtide for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dosing of Lipovirtide
Trial: NCT05778864
Drug: LY3473329
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05780801
Drug: Allogeneic Microbiota in Glycerol (10%) (AMG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with positive MDRO cultures will receive MT instilled via a functional feeding tube when in place or rectal enema (when a functional feeding tube is not present) with the rate adjusted to the recipient's clinical status and infusion tolerance.
Trial: NCT02388477
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antibiotic used to treat infection
Trial: NCT04657133
Drug: Standard medication therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medication therapy will be performed according to the national and international guidelines.
Trial: NCT05524519
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Health education: Properly explain the causes and precautions of the patient and instruct the patient to rest regularly. In addition, care should be enhanced to avoid accidents.~2. The basic therapeutic drug is the use of one or more antidepressants, such as oral 5-hydroxytryptamine reuptake inhibitors, dual inhibitors of pentraxin and norepinephrine reuptake, noradrenergic and specific pentraxinergic antidepressants, pentraxin receptor balance antagonists, tricyclic antidepressants, etc. If there is significant sleep disturbance, benzodiazepines may be added temporarily. Dosing and dosage will be adjusted by a specialist.
Trial: NCT05561816
Drug: Hydroxymethylquinoxalindioxyde
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dioxidin®, 0.025% solution for local and external use (Valenta Farm, Russia).
Trial: NCT05745337
Drug: As needed pharmacological rate control with beta-blocker (metoprolol tartrate, metoprolol succinate) or calcium channel blocker (diltiazem, verapamil)
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will stop their daily beta-blocker and take as-needed rate control (beta-blocker or calcium channel blocker) guided by their implantable cardiac monitor
Trial: NCT06097533
Drug: Cannabisextrakt Avextra 10/10 Lösung
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medical cannabinoids
Trial: NCT06247345
Drug: ADEL-Y01 - healty participants
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In our Part 1 clinical trial, we plan to enroll up to 40 healthy participants, aged 18 to 65, to test the safety and tolerability of ADEL-Y01. The study is divided into 5 cohorts, each with 8 participants, where 6 receive a single dose of ADEL-Y01. Screening is done 28 days prior, followed by randomization and dosing. Participants undergo initial assessments until Day 4 and additional safety and PK evaluations over 12 weeks. Starting at 2.5 mg/kg, the ADEL-Y01 dose may increase up to 100 mg/kg based on Safety Review Committee assessments, ensuring a detailed evaluation of the drug's safety.
Trial: NCT06247345
Drug: Placebo - Healthy Participants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part 1 of our trial, we will enroll 2 placebo participants per cohort in up to 5 cohorts, undergoing the same protocol as those receiving ADEL-Y01 but with a placebo. They'll be part of the study from Day -1 to Day 4 for initial assessments and continue for 12 weeks for further safety and PK evaluations. This inclusion of placebo groups ensures a blinded study design for unbiased comparison of ADEL-Y01's safety and efficacy.
Trial: NCT06247345
Drug: ADEL-Y01 - MCI/AD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part 2 of our trial, we assess ADEL-Y01 in 33 participants aged 50 to 80 with MCI or mild AD, administering multiple IV doses every 2 weeks for 12 weeks. Each of the 3 cohorts will have 8 participants receiving ADEL-Y01, totaling 6 doses. After initial screening and consent, participants are randomized to start treatment on Day 1, with a follow-up in the clinical research unit for safety assessments. Additional safety and PK assessments occur bi-weekly up to 22 weeks, based on the start from the last dose on Day 71.~Doses are set at 7.5, 20, and 50 mg/kg, adjusted based on Part 1 results and SRC safety reviews after at least 3 doses over 6 weeks. This phase focuses on understanding ADEL-Y01's safety and efficacy in AD patients through a cautious dosing strategy.
Trial: NCT06247345
Drug: Placebo - MCI/AD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part 2 of our clinical trial focusing on patients with MCI or mild AD, alongside the active treatment groups, we plan to include placebo groups within the 3 cohorts. Out of the 33 participants aged 50 to 80, 3 in each cohort, totaling 9 participants, will receive a placebo instead of the active drug, ADEL-Y01, administered every 2 weeks for 12 weeks. These placebo participants undergo the same screening, consent, and randomization procedures as those receiving the active drug. They are administered the placebo following the same schedule as the active groups, ensuring a controlled and blinded study environment to accurately assess ADEL-Y01's effects without bias.~Placebo participants are crucial for comparing the active drug's impact on safety, tolerability, and effectiveness against a non-therapeutic intervention, maintaining the study's integrity and providing a benchmark for evaluating ADEL-Y01's true pharmacological effects on MCI or mild AD conditions.
Trial: NCT05170958
Drug: LBL-024 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LBL-024 was given every three weeks for treatment
Trial: NCT06091943
Drug: Histology-Based Chemotherapy Doublet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy Doublet 1: Cisplatin/carboplatin + pemetrexed.~Chemotherapy Doublet 2: Carboplatin + paclitaxel/nab-paclitaxel.~Choice of histology-based induction chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously.
Trial: NCT04244981
Drug: Fresh Frozen Plasma
RxNorm normalized name: Fresh frozen plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When APTT is prolonged (\> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 6～10 mL/kg FFP.
Trial: NCT06474520
Drug: Calculus bovis sativus (CBS)
RxNorm normalized name: Mycobacterium bovis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will orally receive 100mg CBS per day from day 1 to day 84.
Trial: NCT06014853
Drug: SOL-804-F
RxNorm normalized name: F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with water on the administration day of each period.
Trial: NCT05291546
Drug: REGN9035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: Single dose administered by IV infusion on day 1. Part B: Selected doses administered by IV infusion on day 2 or 22.
Trial: NCT05291546
Drug: REGN5381
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B: Selected doses administered by IV infusion on day 1.
Trial: NCT04930861
Drug: Covidir injections
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of the investigational product CODIVIR at a dose of 20 mg twice a day subcutaneously.
Trial: NCT06547333
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05808010
Drug: Weifuchun+Hydrotalcite/L-Glutamine and Sodium Gualenate Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally delivered tablets for 7 months. Take it according to the instructions.
Trial: NCT05081167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT04990063
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy drug
Trial: NCT05769855
Drug: HR18034
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR18034 380mg
Trial: NCT06221761
Drug: not using antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no antibiotic application
Trial: NCT06221761
Drug: using antibiotic
RxNorm normalized name: Antibiotics for systemic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibiotic application
Trial: NCT05895877
Drug: Goofice®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily before breakfast.
Trial: NCT05895877
Drug: Goofice® Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily before breakfast.
Trial: NCT05725512
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone tablets (20 mg daily for 6 weeks, 10 mg daily for 1 week, 5 mg daily for 1 week) or identical placebo tablets for 8 weeks
Trial: NCT05725512
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo identical to prednisolone tablets
Trial: NCT05844111
Drug: [14C]-BGB-11417
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of liquid formulation
Trial: NCT05292495
Drug: HR17031 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR17031 injection; administered subcutaneously.
Trial: NCT05577000
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04985201
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg daily oral tablet taken.
Trial: NCT04303000
Drug: Opioid Overdose Education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online audiovisual training focused on recognizing the signs of an opioid overdose and administering naloxone. Participants are provided with information on where they can obtain a naloxone kit.
Trial: NCT06318845
Drug: DHP2302R1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg per dose, once daily
Trial: NCT06318845
Drug: DHP2302R2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg per dose, once daily
Trial: NCT06537765
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All women with endometriosis in all groups (A, B, \& C) will receive their medical treatment as prescribed by the gynecologist.
Trial: NCT04701606
Drug: Artecom® (pyronaridine-artesunate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \* Participant body weight (Artecom® dose)~* ≥ 65kg (Artecom® 4 tablets: Pyronaridine 720mg/ Artesunate 240mg)~* ≥ 45kg and \< 65kg (Artecom® 3 tablets: Pyronaridine 540mg/ Artesunate 180mg)
Trial: NCT04701606
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \* Participant body weight (Placebo dose)~* ≥ 65kg (Placebo 4 tablets)~* ≥ 45kg and \< 65kg (Placebo 3 tablets)
Trial: NCT05626140
Drug: Codeine Phosphate
RxNorm normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Codeine Phophate is an opioid with centrally acting pain alleviating mechanisms, shorter half life and metabolized to morphine in he body which is its active metabolite
Trial: NCT05626140
Drug: Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium is a Cox 2 inhibitor non steroidal anti inflammatory drug with a half life of only 1.2 hrs but a longer action of duration due to its property to get distributed to synovial fluids. metabolized to hydroxy diclofenac and excreted via urine and bile both.
Trial: NCT00002140
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002140
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06652412
Drug: Ultrafractionated RT and CGA Guided systemic treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in cohort 1, all patients will receive Ultrafractionated RT (1Fx every 3 or 4weeks) and Sintilimab (q3w). Furthermore, CGA will assess all patients and classify them into Frail, Vulnerabe, or Fit. Frail patients will receive Best Supportive Care (BSC); Vulnerabe patients will receive Fluorouracil/Raltitrexed and BSC; Fit patients will receive Fluorouracil/Raltitrexed, Oxaliplatin/Irinotecan, and BSC.
Trial: NCT06652412
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-Fluorouracil or capecitabine
Trial: NCT06093308
Drug: Deuremidevir Hydrobromide Tablets
RxNorm normalized name: hydrobromic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple administration, oral administration after meals, D1: 0.6g, twice a day; D2-D5: 0.3g, twice a day; D6: 0.3g, administered once in the morning
Trial: NCT05504187
Drug: KP104
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KP104 will be administered.
Trial: NCT05740631
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assignment of treatment placebo will be started (randomized) after the study visit and placebo will be administered orally in a single-blind fashion for 21 days.
Trial: NCT05157971
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05157971
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05157971
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT
Trial: NCT05556083
Drug: Placebo oral tablet and Dapoxitine 3mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single blind placebo randomized controlled trial
Trial: NCT04979793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk powder placebo
Trial: NCT05159687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator: Placebo Matching placebo will be identical in appearance to the active treatment pill. BID (morning and late afternoon)
Trial: NCT06106009
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution, oral suspension or solid oral formulation(s)
Trial: NCT05143528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule
Trial: NCT05755932
Drug: HFA MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Dose formulation: MDI~* Unit dose strength(s): Reference (propellant only)~* Dosage level(s): 6 inhalations, BID~* Route of administration: Oral inhalation~* Participants will receive treatment B in 1 of 2 possible treatment sequences: AB or BA.
Trial: NCT05501080
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aldosterone receptor antagonists are recommended by guidelines for the treatment of bilateral primary aldosteronism.
Trial: NCT04952597
Drug: Concurrent Chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.~Etoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles~Thoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)
Trial: NCT05739851
Drug: DA-1229_01 2.5/500mg (Before)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration (one tablet once a day)
Trial: NCT05739851
Drug: DA-1229_01 2.5/500mg (After)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration (one tablet once a day)
Trial: NCT05563753
Drug: ABT
RxNorm normalized name: Abtrim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: any antibiotic therapy in the first week of life
Trial: NCT00002137
Drug: Tecogalan sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05834296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT05033886
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT05289323
Drug: Dextrose 5%/Nacl 0.9% Inj
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one ml of normal saline 0.9 % will be mixed with 4 ml dextrose 5 % in the five-milliliter syringe. 0.2 ml of this mixture will be prepared at a one-milliliter identical syringe.
Trial: NCT02603458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive two IV placebo infusions 1 week apart, each lasting 1 minute.
Trial: NCT05535023
Drug: SAR444245
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by vein (IV)
Trial: NCT04620772
Drug: Cyclophosphamide injection
RxNorm normalized name: cyclophosphamide Injection
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide vs placebo
Trial: NCT04903327
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excipient solution
Trial: NCT05107011
Drug: LBL-015 for Injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose - MTD ; Q2W ; intravenous infusion
Trial: NCT05645107
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC infusion pump
Trial: NCT05111002
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg tablet orally twice daily
Trial: NCT05844735
Drug: SAR441566
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT05844735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT06340724
Drug: Banxiaxiexin decotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml liquid-medicine twice daily
Trial: NCT06662253
Drug: Anti-Xa Guided Dosing of Low Molecular Weight Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Enoxaparin 0.5 mg/kg twice daily (rounded up or down to the nearest 10 mg) the initial starting dose. Dose adjustments will be made based on trough levels drawn between the 3rd and 4th dose. The target anti-Xa level range is between 0.1 and 0.2 IU/mL. If the patient is below the target range, then the next Enoxaparin dose will be increased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. If the patient is above the target range, then the next Enoxaparin dose will be decreased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. This dose will be maintained until hospital discharge.